Association of -24CT, 1249GA, and 3972CT ABCC2 Gene Polymorphisms with Methotrexate Serum Levels and Toxic Side Effects in Children with Acute Lymphoblastic Leukemia

REFERENCES

• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–178.
   PubMed Web of Science ®Google Scholar
• Imanishi H, Okamura N, Yagi M, Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet. 2007;52:166–171.
   PubMed Web of Science ®Google Scholar
• Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin Hematol. 2009;46:52–63.
   PubMed Web of Science ®Google Scholar
• Evans WE, Crom WR, Abromowitch M, Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med. 1986;314:471–477.
   PubMed Web of Science ®Google Scholar
• Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum. 1996;39:1951–1960.
   PubMed Web of Science ®Google Scholar
• Hooijberg JH, Broxterman HJ, Kool M, Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999;59:2532–2535.
   PubMed Web of Science ®Google Scholar
• Zeng H, Chen ZS, Belinsky MG, Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001;61:7225–7232.
   PubMed Web of Science ®Google Scholar
• Chen ZS, Lee K, Walther S, Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002;62:3144–3150.
   PubMed Web of Science ®Google Scholar
• Costea I, Moghrabi A, Laverdiere C, Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica. 2006;91:1113–1116.
   PubMed Web of Science ®Google Scholar
• Aplenc R, Thompson J, Han P, Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res. 2005;65:2482–2487.
   PubMed Web of Science ®Google Scholar
• Huang L, Tissing WJ, de Jonge R, Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia. 2008;22:1798–1800.
   PubMed Web of Science ®Google Scholar
• Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev. 2007;26:183–201.
   PubMed Web of Science ®Google Scholar
• Vlaming ML, van Esch A, Pala Z, Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther. 2009;8:3350–3359.
   PubMed Web of Science ®Google Scholar
• Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther. 2006;112:457–473.
   PubMed Web of Science ®Google Scholar
• Rau T, Erney B, Gores R, High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther. 2006;80:468–476.
   PubMed Web of Science ®Google Scholar
• Laechelt S, Turrini E, Ruehmkorf A, Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J. 2011;11:25–34.
   PubMed Web of Science ®Google Scholar
• Ranganathan P, Culverhouse R, Marsh S, Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African-American patients with rheumatoid arthritis. J Rheumatol. 2008;35:572–579.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth Edition ed. Lyon, France: IARC Press; 2008.
   Google Scholar
• Haenisch S, Zimmermann U, Dazert E, Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J. 2007;7:56–65.
   PubMed Web of Science ®Google Scholar
• Relling MV, Fairclough D, Ayers D, Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol. 1994;12:1667–1672.
   PubMed Web of Science ®Google Scholar
• Wall AM, Gajjar A, Link A, Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia. 2000;14:221–225.
   PubMed Web of Science ®Google Scholar
• Kishi S, Cheng C, French D, Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007;109:4151–4157.
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Mori T, Torii C, Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2008;30:347–352.
   PubMed Web of Science ®Google Scholar
• Pakakasama S, Kanchanakamhaeng K, Kajanachumpol S, Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia. Ann Hematol. 2007;86:609–611.
   PubMed Web of Science ®Google Scholar
• Sookoian S, Castano G, Burgueno A, Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. J Hepatol. 2008;48:125–132.
   PubMed Web of Science ®Google Scholar
• Hoblinger A, Grunhage F, Sauerbruch T, Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 Gene (MRP2/ABCC2) with susceptibility to bile duct cancer. Digestion. 2009;80:36–39.
   PubMed Web of Science ®Google Scholar
• Haenisch S, May K, Wegner D, Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics. 2008;18:357–365.
   PubMed Web of Science ®Google Scholar